CoChat

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1

Anderson, Gülsüm, Gries, Margarete, Kurihara, Noriyoshi, Honjo, Tadashi, Anderson, Judy, Donnenberg, Vera, Donnenberg, Albert, Ghobrial, Irene, Mapara, Markus Y., Stirling, David, Roodman, David, Lentzsch, Suzanne · 2006 · Blood
Cited by 149

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

CC-4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage. Early osteoclast progenitors are of hematopoietic origin and differentiate into mature bone resorbing multinucleated osteoclasts. We investigated the effects of CC-4047 and thalidomide on human osteoclastogenesis, using in vitro receptor activator of NFκ-B ligand/macrophage colony-stimulating factor–stimulated bone marrow cell cultures. Treating bone marrow cultures with CC-4047 for 3 weeks decreased osteoclast formation accompanied by complete inhibition of bone resorption. The inhibitory effect was similar when cultures were treated for 3 weeks or for only the first week (90% inhibition), indicating that CC-4047 inhibits early stages of osteoclast formation. Inhibition of osteoclastogenesis by CC-4047 was mediated by a shift of lineage commitment to granulocyte colony-forming units at the expense of granulocyte-macrophage colony-forming units. Further studies revealed that this shift in lineage commitment was mediated through down-regulation of PU.1. Treatment with thalidomide resulted in significantly less potent inhibition of osteoclast formation and bone resorption. These results provide evidence that CC-4047 blocks osteoclast differentiation during early phases of osteoclastogenesis. Therefore, CC-4047 might be a valuable drug for targeting both tumors and osteoclastic activity in patients with multiple myeloma and other diseases associated with osteolytic lesions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2005-08-3450

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 149

Metadata

Authors
Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V., Donnenberg, A., Ghobrial, I., Mapara, M. Y., Stirling, D., Roodman, D., & Lentzsch, S.
Venue
Blood
Published
2006-04-15
Volume
107
Issue
8
Pages
3098-3105
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2140017817
Cited by
149
References
15
FWCI
2.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. https://app.cochat.ai/papers/10.1182/blood-2005-08-3450
The paper
Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V., Donnenberg, A., Ghobrial, I., Mapara, M. Y., Stirling, D., Roodman, D., & Lentzsch, S. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. https://doi.org/10.1182/blood-2005-08-3450

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.